期刊文献+

慢性心力衰竭患者临床管理与评估 被引量:3

Management and Assessment in Patients with Chronic Heart Failure
下载PDF
导出
摘要 尽管近年来在慢性心力衰竭(CHF)的治疗方面取得了较大的进展,但CHF患者仍有较高的住院率及病死率。CHF临床实践指南的发布促进了规范化治疗。为了取得良好的医疗效果,临床医生必须对心力衰竭患者提供一系列复杂的药物治疗及严格的自我控制措施。随着医学的不断发展,出现了包括心脏再同步化起搏、左心室辅助装置或心脏移植等治疗,而这些手段常需要在对患者进行危险性评估的基础上进行。严格遵循指南并使CHF患者出院后的教育与各种支持项目相结合才能够在一定程度上减低患者的再住院率及病死率。 Despite advances in the treatment of patients with chronic heart failure (HF), these patients remain at high risk for hospitalization and death. To summarize the goals of heart failure care, clinical practice guidelines have been published by several organizations. Physicians treating patients with heart failure due to HF must prescribe a complex treatment plan involving multiple medications and rigorous self--care practices to achieve optimal care. Timing for the introduction of oth- er therapies, including resynchronization pacing, left ventricular assist devices, or cardiac transplantation, often is based on an assessment of patient risk. Optimal pharmacotherapy according to guideline and the effects of heart failure patient discharge education combined with various post--discharge support programs have demonstrated benefits with respect to reductions in hospitalizations and mortality.
出处 《医学与哲学(B)》 2013年第6期24-27,共4页 Medicine & Philosophy(B)
关键词 心力衰竭 管理 评估 heart failure, management, assessment
  • 相关文献

参考文献24

  • 1Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection frac- tion: networkmeta-analysis[J]. BMJ, 2013, 346(1):1-10.
  • 2Rostagno C. Six-minute walk test: independent prognostic mark-er? [J]. Heart, 2010,96(2):97-98.
  • 3Cesar Mde C, Montesano F T, Diniz R V, et al. Cardiopulmonary responses to exercise in patients of different age group with conges tive heart failure[J]. Arq Bras Cardiol,2006,86(1) : 14- 18.
  • 4O'connor C M, Whellan D J, Wojdyla D, et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score mod- el[J]. Cire Heart Fail, 2012, 5(1):63-71.
  • 5Oh C, Chang H J, Sung J M, et al. Prognostic Estimation of ad vanced heart failure with low left ventrieular eiection fraction and wideQRSinterval[J]. Korean Cire J, 2012, 42(10): 659-667.
  • 6Mak G S, DeMaria A, Clopton P, et al. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: com parison with tissue Doppler imaging recordings[J]. Am Heart J, 2004,148(5) :895-902.
  • 7Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure[J]. Eur Heart J, 2012, 33(17):2135-2142.
  • 8Yoshioka D, Sakaguchi T, Saito S, et al. Predictor of early mortal- ity for severe heart failure patients with left ventricular assist de vice implantation: significance of INTERMACS level and renal function[J]. CircJ, 2012, 76(7):1631-1638.
  • 9van der Wal M H, Jaarsma T, van Veldhuisen D J. Non-compli- ance in patients with heart failure: how can we manage it? [J]. Eur J Heart Fail, 2005,7(1) :5-17.
  • 10崔荣昌.基层医院慢性心力衰竭药物治疗现状及规范化治疗研究[J].中国医药导报,2012,9(6):110-112. 被引量:11

二级参考文献36

  • 1吴学思.正确掌握β受体阻滞剂在慢性心力衰竭的应用时机[J].中华心血管病杂志,2006,34(9):769-771. 被引量:62
  • 2曹雅旻,胡大一,王宏宇,吴彦.我国基层医院慢性心力衰竭药物治疗现状调查[J].中华内科杂志,2006,45(11):907-909. 被引量:72
  • 3Neuberger HR, Mewis C, van Veldhuisen DJ, et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J, 2007,28 : 2568-2577.
  • 4Efremidis M,Pappas L,Sideris A,et al. Management of atrial fibrillation in patients with heart failure. Cardiae Fail, 2008, 14 : 232-237.
  • 5Dries DL,Exner DV,Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD Trials. J Am Coll Cardiol,1998,32:695-703.
  • 6Cha YM, Redfield MM, Shen WK, et al. Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation, 2004,109 : 2839-2843.
  • 7de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation A meta-analysis. Arch Intern Med, 2005,165 :258-262.
  • 8Hagens VE,Crijns HJ ,Van Veldhuisen DJ. et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAte Control versus Electrical cardioversion(RACE) study. Am Heart J,2005,149:1106-1111.
  • 9Shelton RJ, Clark AL, Goode K, et al. A randomized, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure:(CAFE- Ⅱ Study). Heart,2009,95 : 924-930.
  • 10Freudenberger RS, Wilson AC, Kostis J B, et al. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction(from the AFFIRM Study). Am J Cardiol, 2007,100 : 247-252.

共引文献43

同被引文献19

  • 1杨溶海,方长庚,梁建光.丹参多酚酸盐对冠心病心力衰竭患者左心功能及血清心型脂肪酸结合蛋白的影响[J].中国老年学杂志,2014,34(9):2322-2324. 被引量:37
  • 2韩雅玲,臧红云,王冬梅,荆全民,王守力,王祖禄.冠状动脉介入治疗联合心脏再同步化治疗缺血性心肌病顽固性心力衰竭[J].中华心血管病杂志,2005,33(1):17-21. 被引量:30
  • 3Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldoste- rone-induced vascular fibrosis[J]. Arterioscler Thromb Vasc Biol, 2013,33(1) :67-75.
  • 4Dumic J, Dabelie S, Flogel M. Galectin-3 .. an open-ended story[J]. Biochim Biophys Acta, 2006,1760(4) : 616- 635.
  • 5Ho J E, Liu C,Lyass A, et al. Galectin 3,a marker of cardiac fibro- sis,predicts incident heart failure in the community[J]. J Am Coil Cardiol, 2012,60 (14) : 1249 - 1256.
  • 6Sharma U C,Pokharel S, van Brakel T J, et al. Galectin-3 marks activa- ted macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J]. Circulation, 2004,110 (19) : 3121 - 3128.
  • 7de Boer R A, Voors A A, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression[J]. Eur J Heart Fail,2009,11(9) :811-817.
  • 8Hrynchyshyn N,Jourdain P,Desnos M,et al. Galectin 3:a new bio- marker for the diagnosis, analysis and prognosis of acute and chron- ic heart failure[J]. Arch Cardiovasc Dis, 2013,106 (10) : 541 - 546.
  • 9van Kimmenade R R,Januzzi J L,Ellinor P T,et al. Utility of ami- no-terminal pro-brain natriuretic peptide, galectin 3, and apelin for the evaluation of patients with acute heart failure[J]. J Am Coil Cardiol,2006,48(6) :1217-1224.
  • 10de Boer R A, Lok D J,Jaarsma T, et al. Predictive value of plasma galeetin-3 levels in heart failure with reduced and preserved ejection fraction[J]. Ann Meal,2011,43(1):60-68.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部